Kite Pharma to Present at the 2015 Jefferies Immuno-Oncology Summit in Boston
SANTA MONICA, Calif., April 10, 2015 (GLOBE NEWSWIRE) — Kite Pharma, Inc., (KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT(TM)) products for the treatment of cancer, today announced that Arie Belldegrun, M.D., FACS, Chairman, President and Chief Executive Officer, will present a company overview at the 2015 Jefferies Immuno-Oncology Summit in Boston. The presentation will take place on Wednesday, April 15, 2015, at 8:10 a.m. EDT.
About Kite Pharma
Kite Pharma, Inc., is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, with a primary focus on eACT(TM) designed to restore the immune system’s ability to recognize and eradicate tumors. Kite is based in Santa Monica, CA. For more information on Kite Pharma, please visit www.kitepharma.com.
- Health Care Industry
- Kite Pharma
Kite Pharma Cynthia M. Butitta Chief Financial Officer and Chief Operating Officer 310-824-9999 For Media: Justin Jackson For Investor Inquiries: Lisa Burns and Nancy Yu Burns McClellan 212-213-0006 email@example.com firstname.lastname@example.org email@example.com